Switch to DTG plus 3TC for HIV patients with TDF side effects
Treatments studied
Part of Immune system & allergy, Infections clinical trials.
This trial tests whether switching (or continuing) treatment with dolutegravir (DTG) plus lamivudine (3TC) works as well and is better tolerated in adults with HIV that is already controlled. It is specifically for people who have possible kidney (TDF-related) or bone side effects from their current TDF-based regimen.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been taking TDF plus 3TC or FTC without breaks for at least 6 months
- Your HIV is well controlled: HIV viral load was under 40 copies/mL in the last 6 months and at screening
- You have signs your kidneys may be affected by TDF (TDF-related kidney toxicity) and/or bone loss from TDF
- You are able to attend visits regularly and sign the consent form
- If you could become pregnant, you must have a negative pregnancy test and use reliable birth control during the study
- Your kidney function must be strong enough: creatinine clearance must be at least 30 mL/min
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether taking dolutegravir plus lamivudine (a simpler two-drug regimen) can work as well as a standard three-drug HIV regimen for people who have reasons they can’t stay on the usual medicines. You may be offered free treatment if you meet the safety checks and can attend follow-up visits.
This trial tests better ways to manage HIV when the virus becomes resistant to dolutegravir (DTG), a key medicine. It is for people with high viral load despite being on DTG for at least six months.
This Phase 3 study tests whether switching from a three-drug HIV regimen to a two-drug regimen (doravirine plus dolutegravir) can keep your virus levels controlled. It may help people who are stable on their current treatment explore a simpler switch under close monitoring.
This study tests whether switching your current HIV medication to a daily pill with doravirine, dolutegravir, and lamivudine is safe and effective. It is for people whose HIV is well-controlled but who have had to change treatment before because it stopped working.
This trial tests a two-drug HIV treatment (dolutegravir and lamivudine) for people who also have active TB and are taking a standard TB medicine called rifampin. It is designed for those who have not yet started HIV treatment.
This trial tests if switching to a two-drug combination of dolutegravir and lamivudine is safe and effective for transgender women who already have undetectable HIV levels on a three-drug regimen. It aims to simplify treatment and reduce side effects.
Hear when a new Acquired Immunodeficiency Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.